349 results about "RA - Rheumatoid arthritis" patented technology

The invention belongs to the technical field of biological medicine, and particularly relates to application of diindolymethane and the derivant thereof in rheumatoid arthritis and preparation of novel aqueous solution preparation of diindolymethane and the derivant thereof. The diindolymethane and the derivant thereof can effectively improve the level of interferon - Gamma in vitro and in vivo and can regulate the immunity of the organism, thereby stopping the happening and development of diseases and reducing the injury caused by the diseases. In addition, the intermediary mainly involved in the water solution preparation of the product is cyclodextrin. The water solution preparation of the product can effectively improve the water solubility, and is convenient for use. The application of the water solution preparation of the product is not limited only within the application on treatment of rheumatoid arthritis, but also includes the application of diindolymethane and the derivant thereof in treatment of other diseases, such as tumor and androgen and estrogen related diseases.

The invention develops a simplified method for the in-vitro isolation and expansion of umbilical mesenchymal stem cells (MSCs) and confirms that the MSCs obtained by the method have the effects of immunoregulation and inflammation inhibition in the treatment of rheumatoid arthritis.

The invention discloses a single-chain antibody of human source anti-alexin C3d molecules. A light chain and a heavy chain of the antibody have a unique CDR region; excellent antigen binding activityis realized; the affinity constant reaches 1.22*10<-7> mol/L. Biological distribution experiments prove that the anti-C3d single-chain antibody provided by the invention can be highly gathered in thearthritis positions after entering a mouse model with rheumatoid arthritis; the arthritis serious degree of the three ScFv treatment groups is obviously lower than that of a PBS group; the healing degree has the obvious dose dependency relationship; the result shows that the excellent anti-adhesion/ anti-inflammatory targeted inhibition effects are achieved. In the treatment process on MRL/lpr mice with lupus erythematosus, the anti-C3d single-chain antibody provided by the invention can obviously improve the survival rate of the mice; the symptoms of proteinuria, glomerular score, interstitial inflammation, vasculitis and crescent/necrosis and the like in the treatment group are obviously relieved. The result shows that the anti C3d single-chain antibody provided by the invention has excellent application prospects in the preparation of medicine for treating autoimmune diseases.

The invention relates to a preparation and applications of a paeonol controlled-release preparation in the technical field of the medicine. The paeonol controlled-release preparation refers to a group of controlled-release and long-time effective preparations which contain the microspheres and gel matrix tablets used for preparing tablets or capsules, and thermosensitive in situ gel for external use, wherein the specifications of the prepared paeonol controlled-release preparation are 60mg and 120mg; under special conditions, the accumulative release rate at 2h is less than 20% of the labeled amount, the accumulative release rate at 6h is 40-60% of the labeled amount and the accumulative release rate at 12h is more than 80% of the labeled amount respectively; and the paeonol controlled-release preparation can be used to cure rheumatoid arthritis. By using the thermosensitive in situ gel for external use, the preparation residence time of the affected part can be significantly prolonged.

The invention discloses a warm compression thermal therapy liquid for treating rheumatoid arthritis, postpartum rheumatism, scapulohumeral periarthritis, lumbar muscle degeneration, sciatica, lumbar vertebra pain, cervical vertebra pain, hemiplegia and stroke. The warm compression thermal therapy liquid is mainly prepared from double-teeth pubescent angelica root, wild ginger, himalayan teasel root, dandelion, longhairy antenoron herb, fortune's drynaria rhizome, Chinese taxillus twig, astragalus, cortex eucommiae, scorpio, red paeony root, white paeony root, orientvine, prepared rehmannia rhizome, achyranthis bidentatae, large-leaved gentian and red-rooted salvia root according to a certain weight proportion. A preparation method of the warm compression thermal therapy liquid comprises the following steps of: preparing the selected Chinese medicines, extracting, purifying and smashing with a smasher; and applying according to three kinds of methods. The warm compression thermal therapy liquid has the effects of clearing and activating the channels and collaterals, regulating tendons and qi, dispelling cold and drawing poison out, can be used for quickly improving microcirculation and enhancing the immunologic function and temperature resistance of an organism, is applied to treatment of a plurality of incurable miscellaneous diseases such as rheumatoid arthritis, scapulohumeral periarthritis, postpartum rheumatism, sciatica, cervical vertebra lumbar vertebra pain, hemiplegia and stroke and the like, and has quick response and a high curative rate.

The invention provides an RANKL-TNF (Receptor Activator of Nuclear Factor Kappa-B Ligand-Tumour Necrosis Factor) sample region fusion protein, and in particular relates to a fusion protein of an RANKL-TNF sample region protein and a Th2 cell epiposition segment with broad host range property. An experiment shows that an antibody produced by an RANKL-TNF sample region fusion protein immune mouse has the effect of combining RANKL with TNF-alpha, can be used for treating diseases such as rheumatoid arthritis and the like and can play effects of antagonistic bone destruction and inflammation inhibition. The RANKL-TNF sample region fusion protein disclosed by the invention can be used as a therapeutic vaccine and provides a new therapeutic approach and thinking for the diseases such as rheumatoid arthritis and the like. According to the invention, the RANKL-TNF sample region fusion protein is expressed in vitro, and therefore the method has the advantages of high expression yield, strong controllability and relatively low production cost;, and the product has good immunogenicity and is easy to realize mass production.

The invention relates to a traditional Chinese medicine composition for improving joint gall of rheumatoid arthritis and a preparation method thereof. The traditional Chinese medicine comprises the following raw materials: shinyleaf pricklyash root, kadsura longepedunculata, cortex acanthopanacis, tinospora sinensis merr, clematis chinensis, cissus pteroclada hayata, sargentodoxa cuneata and Chinese starjasmine stem, and is applied to joint gall caused by wind, cold, wet, phlegm and blood stasis obstruction of meridians and collaterals. The effective constituents of the traditional Chinese medicine composition provided by the invention are the following raw materials: shinyleaf pricklyash root, kadsura longepedunculata, cortex acanthopanacis, tinospora sinensis merr, clematis chinensis, cissus pteroclada hayata, sargentodoxa cuneata and Chinese starjasmine stem. The traditional Chinese medicine composition has a remarkable curative effect on the aspect of improving joint gall of the rheumatoid arthritis, and the effect is superior to that of the prior art.

The invention relates to a traditional Chinese medicine and a preparation method thereof, in particular to an external use drug for treating rheumatoid arthritis and a preparation method thereof. The external use drug comprises, by weight, of 8-12 parts of cassia twig, 18-22 parts of drynaria rhizome, 18-22 parts of radix rehmanniae, 18-22 parts of rehmannia glutinosa, 18-22 parts of herbaceous peony red root, 28-32 parts of lycopodium clavatum, 10-14 parts of silkworm larva, 8-12 parts of dried body of ground beetle, 8-10 parts of ephedra, 8-10 parts of qiang radix angelicae pubescentis, 8-10 parts of radices sileris and 16-20 parts of radix achyranthis bidentatae. All constituents are made into fine powder to be filled in a medicine bag in a shape of a double-layer glove or double-layer sock. When the external use drug is used, the vinegar is sprayed on the surface of the medicine bag which is placed in a microwave oven to heat 2 minutes, a patient lime with a glove or sock made of pure cotton is sleeved in the medicine bag, the medicine bag can be repeatedly heated, and a patient wears the drug glove or sock for 30-40 minutes each time. The external use drug for treating the rheumatoid arthritis organically bonds various constituents, gives full play to pharmacodynamic effects on the various constituents, absorbs and permeates through skin, has effects on human bodies, is slow in pharmacodynamic effects, can release stably, avoids inconvenience brought by oral medicine, can be easily accepted by the patient and is good in pharmacodynamic effects.

The invention relates to a plaster for treating hyperosteogeny, rheumatism, rheumatoid arthritis and arthritis, which is mainly prepared from the following active pharmaceutical ingredients: long-noded pit viper, cassia twig, raw szechuan aconite, heracleum hemsleyanum michaux, eucommia, radix clematidis, spatholobus stem, club moss, american lopseed, semen momordicae, raw nux vomica, Ningpo yam rhizome, radix sileris, eucommia and the like. The plaster has the advantages of scientific formula and obvious curative effect. Under the synergistic actions of the traditional Chinese medicines, the plaster can perform the functions of expelling wind and clearing away cold, activating blood circulation to dissipate blood stasis, promoting the subsidence of swelling, alleviating pain, nourishing the bone and relaxing tendons, and can promote tissue regeneration, strengthen the body and smooth the meridians, so that the hyperosteogeny is gradually softened, atrophied and healed. Therefore, the plaster has good curative effect on hyperosteogeny, rheumatism, rheumatoid arthritis and arthritis. Clinical application for more than 8 years proves that the plaster has treated 23897 patients with cervical vertebra hyperplasia, knee joint hyperplasia, rheumatism, rheumatoid arthritis, traumatic injury, sprains, lumbar sprain, acute chest pain, stiff neck, strains and lumbar muscle strain, wherein 22056 patients are cured; and thus, the total cure rate is 92.4%.

The present invention provides HAb18G/CD147 function epitone amino acid sequence as shown in the <400>1 or the <400>2 sequence in the sequence list and with serial monoantibody function and the application of the said functional epitone area in preparing medicine for treating tumor recurrence, tumor metastasis, rheumatoid arthritis and osteoarthritis. The found HAb18G/CD147 function area may be used as the targeting molecule in designing, screening and synthesizing its antagonist to block the function of effect cell in inducing and secreting matrix metal protainase, to reduce the degradation of tumor tissue interstitium, joint cartilage erosion and nascent vascularization and to treat tumor recurrence, tumor metastasis, rheumatoid arthritis and osteoarthritis. Therefore, the discovery of the functional epitone has application foreground in developing new medicines.

The invention discloses a traditional Chinese medicine, in particular a traditional Chinese medicine composition for treating rheumatoid arthritis and a preparation method thereof. The traditional Chinese medicine composition for treating rheumatoid arthritis is characterized by comprising the following components: aconitum wardii, grass monkshood, Pinellia ternata, rhizoma arisaematis, nux vomica, hindu hatura flower, pseudo-ginseng, dragon's blood, ligusticum wallichii, turmeric, safflower carthamus, corydalis tuber, root of common peony, vinegary armadillo, radix angelica, vinegary frankincense, vinegary myrrh, ginger, camphor and plum blossom borneol. The traditional Chinese medicine is specially used for treating rheumatoid arthritis and a plurality of medicines are matched properly to improve the curative effect by means of inter-synergism or resistance so as to meet the treating requirement of complex condition. The traditional Chinese medicine reduces the adverse reaction, has rapid effect of external treatment, is convenient for external use, safe and reliable and has good treating or symptom relieving effect for rheumatoid arthritis and cervicodynia, omalgia, lumbago and skelalgia. Totally 660 patients are treated and total effective rate reaches 96%.

The invention relates to the field of chemical medicines and concretely relates to a 1-(pyrimidine-4-yl)-3-aminopiperdine derivative and its preparation method and use. The invention provides the 1-(pyrimidine-4-yl)-3-aminopiperdine derivative. The 1-(pyrimidine-4-yl)-3-aminopiperdine derivative has a structure shown in the formula IV. The invention also provides a preparation method and a use of the 1-(pyrimidine-4-yl)-3-aminopiperdine derivative. The 1-(pyrimidine-4-yl)-3-aminopiperdine derivative can selectively inhibit JAK3 and provide a novel choice for treating JAK3-related diseases such as rheumatoid arthritis, asthma, chronic obstructive pulmonary diseases and tumors.

The invention discloses a fusion protein of a single-chain antibody of a human anti-complement C3d molecule and a complement inhibitor CD59. The antibody has excellent antigen binding activity. Biological distribution experiments prove that the fusion protein provided by the invention can be rapidly and highly aggregated at an arthritis part after entering a rheumatoid arthritis mouse model, and has an excellent anti-adhesion/anti-inflammation targeting inhibition effect. In treatment of MRL/lpr lupus erythematosus mice, the fusion protein provided by the invention can obviously improve the survival rate of the mice, and symptoms of proteinuria, glomerular score, interstitial inflammation, vasculitis, crescent/necrosis and the like of a treatment group are obviously improved, so that the fusion protein provided by the invention has an excellent application prospect in preparation of medicaments for treating autoimmune diseases.

A Chinese medicine for treating rheumatic and rheumatoid arthiritides is prepared from 32 Chinese-medicinal materials including vomiting nut, scorpion, white atractylodes rhizome, borneol, etc. Its preparing process is also disclosed.

To solve the problem of an obvious side effect existing in the traditional Tripterygium Hypoglaucum Hutch root tablet, the invention provides a bi-layer extended release tablet which can reduce medicine peak plasma concentration. A Tripterygium Hypoglaucum Hutch root extract is any one extract of the whole Tripterygium Hypoglaucum Hutch root, Tripterygium Hypoglaucum Hutch root bark, or Tripterygium Hypoglaucum Hutch root core with the bark removed. The Tripterygium Hypoglaucum Hutch extract bi-layer extended release tablet has the characteristics of little untoward effect, and is convenient and safe to use. At the same time, a medicine-time curve is stable, the plasma concentration has small fluctuations, and the half life is prolonged. The Tripterygium Hypoglaucum Hutch root extract extended release bi-layer tablet using the root core with the bark removed has good therapeutic effects on asthma, lupus erythematosus, nephritis, and rheumatoid arthritis.

The invention discloses a medicine for treating rheumatoid arthritis and ankylosing spondylitis and its preparation method, which is mainly prepared from Clematis chinensis, arisaema tuber, cantharis, semen strychni, ledebouriella root, cassia twig and camphor by a predetermined weight ratio, the medicament fits for external use by patients.